leisure time -WSS

leisure time

author：entertainment 2025-10-06 07:54:43 - browse：24184

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Stanford president's case begs question: Who takes blame?

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

FDA warns medical device makers about rise in fabricated data

Texas Department of Public Safety speaks out on migrant abuse allegations

Medicare Advantage enrollment hits roughly 33.4 million

Indian pharmaceutical industry in denial over drug

WATCH: Why do our ears pop?

focus

leisure time

entertainment

Bright Health sells Medicare Advantage business to Molina

Abridge raises $150m as clinical notes automation market heats up

ChatGPT in medicine: STAT answers readers' burning questions

Weight loss drugs aren’t covered by Obamacare. That may change

23andMe had bad news about my health. I wish a person had delivered it

Tocagen's brain cancer gene therapy trial continues. Investors worry

DIEP, the 'gold standard' of breast reconstruction, is under threat

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Anesthesiologist group: stop taking Ozempic before surgery

Medicare Advantage enrollment grows 7.1% to 33.4 million people

focus

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Indian pharmaceutical industry in denial over drug

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Abridge raises $150m as clinical notes automation market heats up

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

explore

hotspot

hotspot

explore